Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis

Thijs T. Jansza, Franka E. van Reekuma, Akin Özyilmazb, c, Pim A. de Jongd, Francisctus T. J. Boereboome, f, Tiny Hoekstrag, Marianne C. Verhaara, Brigit C. van Jaarsvelde, g

aDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; bDivision of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands; cDialysis Center Groningen, Groningen, The Netherlands; dDepartment of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands; eDianet Dialysis Centers, Utrecht, The Netherlands; fDepartment of Internal Medicine, Diakonessenhuis Utrecht, Utrecht, The Netherlands; gDepartment of Nephrology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Keywords
Coronary artery calcification · Hemodialysis · Peritoneal dialysis

Abstract
Background: Vascular calcification is seen in most patients on dialysis and is strongly associated with cardiovascular mortality. Vascular calcification is promoted by phosphate, which generally reaches higher levels in hemodialysis than in peritoneal dialysis. However, whether vascular calcification develops less in peritoneal dialysis than in hemodialysis is currently unknown. Therefore, we compared coronary artery calcification (CAC), its progression, and calcification biomarkers between patients on hemodialysis and peritoneal dialysis. Methods: We measured CAC in 134 patients who had been treated exclusively with hemodialysis (n = 94) or peritoneal dialysis (n = 40) and were transplantation candidates. In 57 of them (34 on hemodialysis and 23 on peritoneal dialysis), we also measured CAC progression annually up to 3 years and the inactive species of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), fetuin-A, osteoprotegerin. We compared CAC cross-sectionally with Tobit regression. CAC progression was compared in 2 ways: with linear mixed models as the difference in square root transformed volume score per year (ΔCAC SQRV) and with Tobit mixed models. We adjusted for potential confounders. Results: In the cross-sectional cohort, CAC volume scores were 92 mm³ in hemodialysis and 492 mm³ in peritoneal dialysis (adjusted difference 436 mm³; 95% CI –47 to 919; p = 0.08). In the longitudinal cohort, peritoneal dialysis was associated with significantly more CAC progression defined as ΔCAC SQRV (adjusted difference 1.20; 95% CI 0.09 to 2.31; p = 0.03), but not with Tobit mixed models (adjusted difference in CAC score increase per year 106 mm³; 95% CI –140 to 352; p = 0.40). Peritoneal dialysis was associated with higher osteoprotegerin (adjusted p = 0.02) but not with dp-ucMGP or fetuin-A. Conclusions: Peritoneal dialysis is not associated with less CAC or CAC progression than hemodialysis, and perhaps with even more progression. This indicates that vascular calcification does not develop less in peritoneal dialysis than in hemodialysis.

© 2018 The Author(s)
Published by S. Karger AG, Basel

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.

Thijs T. Jansz
Department of Nephrology and Hypertension
University Medical Center Utrecht, Utrecht University
PO box 85500, NL–3508 GA Utrecht (The Netherlands)
E-Mail t.t.jansz@umcutrecht.nl
Introduction

Cardiovascular disease is the leading cause of death among patients with end-stage renal disease [1, 2]. This high cardiovascular mortality is strongly associated with vascular calcification [3, 4], which occurs frequently [2] and progresses almost universally in end-stage renal disease [5]. Vascular calcification can be measured at various sites, such as the coronary arteries, and is promoted by phosphate, which is frequently elevated in end-stage renal disease [6, 7].

Remarkably, it is unknown whether vascular calcification is affected by dialysis modality, of which the 2 major types are hemodialysis and peritoneal dialysis. In theory, peritoneal dialysis might induce less vascular calcification than hemodialysis because patients on peritoneal dialysis generally have lower serum phosphate [8] probably owing to their continuous clearance. However, there have never been randomized studies on this subject, as randomization to dialysis modality is generally refused by patients [9]. Moreover, patients on peritoneal dialysis are typically younger and healthier due to the prerequisites of treatment at home [10], which has hampered previous observational research that did not attempt to statistically adjust for this [11–14].

To overcome this, we compared patients treated with hemodialysis or peritoneal dialysis who were all eligible for transplantation and thus relatively comparable in age and comorbidities. First, we compared coronary artery calcification (CAC) cross-sectionally between prevalent patients who had been treated exclusively with hemodialysis or peritoneal dialysis. Second, we compared CAC progression up to 3 years among those who underwent follow-up measurements. Additionally, we studied calcification biomarkers in relation to CAC progression, and compared these between patients on hemodialysis and peritoneal dialysis.

Methods

Cross-Sectional Cohort

We analyzed a cross-sectional sample of patients that had been treated exclusively with conventional hemodialysis or peritoneal dialysis and participated in the NOCTx study. NOCTx (NCT00950573) is a prospective nonrandomized study that included patients on chronic conventional hemodialysis or peritoneal dialysis with a minimum dialysis vintage of 2 months, patients who switched to nocturnal hemodialysis, and patients who received a kidney transplant. Thus, all patients had been treated with hemodialysis or peritoneal dialysis at inclusion. Patients were eligible when aged between 18 and 75 years and were candidates for transplantation when on dialysis. NOCTx excluded patients with a life expectancy <3 months, non-adherence to dialysis regimens, drug abuse, and pregnancy.

Between December 2009 and February 2016, 329 patients were screened for eligibility in 8 Dutch dialysis centers. NOCTx included 181 of these patients, of whom 135 were being treated with hemodialysis and 46 with peritoneal dialysis at inclusion. We excluded patients who were treated with hemodialysis ≥16 h per week (n = 14), as we theorized that more intense dialysis regimens might mitigate calcification. Furthermore, we excluded patients who had a history of treatment with the other modality of over 3 months (n = 33), leaving a sample of 134 patients.

Longitudinal Cohort

We analyzed a longitudinal sample of patients from the NOCTx study who continued treatment with conventional hemodialysis or peritoneal dialysis after inclusion and completed at least one follow-up visit (n = 57). In NOCTx, CAC was measured at inclusion, and after 1, 2 and 3 years. Also, blood was collected in 4.5 mL potassium-ethylenediaminetetraacetic acid vacutainers (on a non-dialysis day in case of hemodialysis), immediately centrifuged and stored in aliquots at –80 °C without thawing at inclusion. Patients left the study if their renal replacement therapy was changed.

Treatment Characteristics

Patients were treated according to the Kidney Disease: Improving Global Outcomes guidelines by the attending nephrologists [15]. Hemodialysis was delivered 3 times a week for 4 h with a default 1.50 mmol/L dialysate calcium concentration, and peritoneal dialysis as automatic or continuous ambulant peritoneal dialysis with a default 1.25 mmol/L dialysate calcium concentration.

CAC Measurements

We determined CAC scores on nonenhanced, prospectively triggered cardiac multi-slice computed tomography (ICT 256, Philips Healthcare, Best, The Netherlands). Acquisiti

Calcification Biomarker Measurements

Plasma levels of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) were determined as described before [17]. The within-run and total variations of this assay were 0.8–6.2% and 3.0–8.2%, respectively. The assay measuring range was between 300 and 12,000 pmol/L and was linear up to 11,651 pmol/L [18]. The dp-ucMGP assays were performed in a single run by the laboratory of Coagulation Profile, department of Biochemistry, Maasstricht, The Netherlands. Plasma fetuin-A and osteoprotegerin levels were measured with a Bio-Plex system (Bio-Rad) multiplex assay by the laboratory of the University Medical Center Utrecht, Utrecht, The Netherlands. All assays were executed in a single run.
Coronary Calcification in HD and PD

Other Study Variables
Study personnel recorded demographic and clinical parameters at inclusion (pre-dialysis blood pressure and post-dialysis weight averaged from routine measurements during 3 hemodialysis sessions or 2 outpatient visits in case of peritoneal dialysis). Laboratory parameters (total calcium, albumin, phosphate, C-reactive protein, and parathyroid hormone) were obtained at inclusion by averaging routine measurements from 3 months, performed with standard laboratory techniques at the local treatment facilities. We classified residual urine production as present (≥100 mL/24 h) or absent. We defined dialysis vintage as the time between the first day of dialysis and the day of scanning, minus the time with a functioning kidney transplant.

Statistical Analyses
We reported normally distributed variables as mean ± SD, non-normally distributed variables as median (interquartile range [IQR]), and categorical data as number (percentage). We compared normally distributed variables with Student t tests, non-normally distributed variables with Mann-Whitney-U tests, and categorical data with chi-square tests.

We compared CAC volume scores cross-sectionally with Tobit regression. Tobit regression can be used to analyze variables with floor and/or ceiling effects [19]. This may be the case with CAC scores, when calcification can be present below the detection limit while the CAC score is 0. With Tobit regression, we assume our outcome variable is actually a normally distributed variable that has been truncated (here CAC score truncated at zero). By modeling this latent underlying variable, values of zero do not need to be excluded from the analyses and do not severely skew the results [19, 20].

To compare CAC progression, we used 2 different approaches, since a valid standard method to analyze CAC progression is lacking. First, we analyzed CAC progression with linear mixed models as change per year in square root transformed volume scores (ΔCAC SQRV). This approach, also known as Hokanson’s method, accounts for interscan variability [21] and has been used by others [22]. We adjusted these analyses for CAC SQRV at inclusion. Second, we used Tobit mixed models to analyze CAC progression. We adjusted for factors known to induce calcification [23]: age (years), sex (male/female), presence of diabetes mellitus (yes/no), dialysis vintage (months), presence of residual urine production ≥100 mL/24 h (yes/no), and vitamin K antagonist use (yes/no).

We used linear regression to compare biomarker levels between dialysis modalities. Dp-ucMGP levels were log-transformed, as these were right-skewed. We adjusted for potential confounders as described above. To determine the relationship between biomarkers and ΔCAC SQRV between inclusion and 1 year, we calculated Pearson’s correlation coefficients.

We report regression coefficients with 95% CI. We considered p values ≤0.05 (2-tailed) statistically significant and used R 3.4.1 (R Foundation Statistical Computing) for all analyses.

Results

Cross-Sectional Cohort
The cross-sectional cohort included 134 patients who had been treated exclusively with hemodialysis (n = 94) or peritoneal dialysis (n = 40). The mean age of this cohort was 54 ± 12 years, 94 (70%) were male, median dialysis vintage was 17 (IQR 10–34) months, and 24 (18%) had diabetes mellitus. The patients on hemodialysis had a median 6-month longer dialysis vintage, were somewhat heavier, had higher blood pressures, and had lower calcium and higher albumin levels than the patients on peritoneal dialysis (Table 1). Phosphate levels were not significantly higher in the patients on hemodialysis. CAC volume scores were 92 (IQR 1–663) in the patients on hemodialysis and 492 (IQR 92–1,139) in the patients on peritoneal dialysis. The distribution of the CAC volume scores is illustrated by a smoothed version of a histogram (Kernel density plot) in online supplementary Figure S1 (for all online suppl. material, see www.karger.com/doi/10.1159/000494665). In Tobit regression, the CAC volume scores were not significantly (p = 0.15) higher in patients on peritoneal dialysis compared to patients on hemodialysis (difference 342 mm³; 95% CI –125 to 808). When adjusted for age, sex, diabetes mellitus, dialysis vintage, residual urine production, and vitamin K antagonist use, peritoneal dialysis was also not significantly (p = 0.08) associated with more CAC than hemodialysis (difference 436 mm³; 95% CI –47 to 919).

Longitudinal Cohort
The longitudinal cohort included 57 patients treated with hemodialysis (n = 34) or peritoneal dialysis (n = 23) who completed at least one follow-up visit. The mean age of this cohort was 52 ± 13 years, 37 (65%) were male, median dialysis vintage was 17 (IQR 8–47) months, and 7 (12%) had diabetes mellitus. The patients on hemodialysis were somewhat heavier, had higher systolic blood pressures, tended to have longer dialysis vintages, tended to use more vitamin K antagonists, and had lower calcium and higher albumin levels than the patients on peritoneal dialysis (Table 1), whereas their other characteristics were comparable. Notably, CAC volume scores at inclusion were not significantly different between patients on hemodialysis (median 163, IQR 5–745) and patients on peritoneal dialysis (median 76, IQR 2–696, p = 0.68), nor was the proportion of patients with zero calcification (n = 8, 24% vs. n = 6, 26%, respectively, p = 0.99). There were also no significant differences between the longitudinal cohort (n = 57) and those who underwent treatment with hemodialysis or peritoneal dialysis after inclusion but did not undergo follow-up CAC measurements (online suppl. Table S1).

The maximum follow-up duration was 1 year for 25 patients, 2 years for 18 patients, and 3 years for 14 patients.
CAC progressed in most patients, but only in 2 of 8 patients on hemodialysis without CAC at inclusion, and in 2 of 6 patients on peritoneal dialysis without CAC at inclusion (Fig. 1). We analyzed CAC progression as $\Delta$CAC SQRV with linear mixed models and with Tobit mixed models.

CAC progressed with 1.72 $\Delta$CAC SQRV per year in patients on hemodialysis (95% CI 0.81 to 2.64) and with 2.73 $\Delta$CAC SQRV per year in patients on peritoneal dialysis (95% CI 1.58 to 3.88; Fig. 2). As can be seen in Table 2, peritoneal dialysis was not significantly ($p = 0.18$) as-

| Table 1. Characteristics of the 134 patients included in the cross-sectional CAC analysis and of the 57 patients included in the CAC progression analyses, stratified by dialysis modality |
|-----------------------------------------------|-----------------------------------------------|
| **Cross-sectional cohort** | **p for difference** | **Longitudinal cohort** | **p for difference** |
| | | | | |
| **Demographics and medical history** | | | | |
| Age, years | 56±11 | 51±15 | 0.06 | 54±12 | 49±14 | 0.17 |
| Male, n (%) | 62 (66) | 32 (80) | 0.16 | 20 (59) | 17 (74) | 0.37 |
| Body mass index, kg/m² | 26.2±4.4 | 24.7±3.3 | 0.05 | 26.7±4.9 | 24.5±3.4 | 0.04 |
| Systolic blood pressure, mm Hg | 143±20 | 135±13 | 0.03 | 142±20 | 132±18 | 0.05 |
| Diastolic blood pressure, mm Hg | 79±12 | 85±10 | <0.01 | 79±11 | 82±14 | 0.29 |
| Diabetes mellitus, n (%) | 21 (22) | 3 (8) | 0.07 | 6 (18) | 1 (4) | 0.28 |
| Cardiovascular disease, n (%) | 23 (25) | 10 (25) | 0.99 | 7 (21) | 5 (22) | 0.99 |
| Current smoker, n (%) | 13 (14) | 5 (13) | 0.99 | 4 (12) | 1 (4) | 0.62 |

| **History of kidney disease** | | | | |
| Dialysis vintage, months | 19 (11–35) | 13 (7–31) | 0.05 | 26 (10–56) | 12 (5–47) | 0.06 |
| Cause of end-stage renal disease, n (%) | | | | |
| Cystic kidney disease | 18 (19) | 6 (15) | 0.42 | 4 (12) | 5 (22) | 0.49 |
| Interstitial nephritis | 5 (5) | 1 (3) | | 2 (6) | 1 (4) | |
| Glomerulonephritis | 24 (26) | 7 (18) | | 9 (26) | 5 (22) | |
| Vascular disease | 21 (22) | 11 (28) | | 8 (24) | 5 (22) | |
| Diabetic nephropathy | 10 (11) | 2 (5) | | 5 (15) | 1 (4) | |
| Other | 8 (9) | 7 (18) | | 4 (12) | 6 (26) | |
| Unknown | 8 (9) | 6 (15) | | 2 (6) | 0 | |

| **Dialysis therapy and kidney function** | | | | |
| Dialysis therapy | | | | |
| Weekly hemodialysis sessions | 3.1±0.5 | – | 2.9±0.3 | – | |
| Weekly hemodialysis hours | 11.4±2.0 | – | 11.0±2.0 | – | |
| Daily peritoneal dialysis dwells | – | 4.4±0.6 | – | 4.3±0.6 | |
| Daily peritoneal dialysis volume, L | – | 9.8±2.4 | – | 9.0±2.2 | |

| Kidney function | | | | |
| Residual urine production ≥100 mL/24 h, n (%) | 55 (59) | 29 (73) | 0.18 | 20 (59) | 14 (61) | 0.99 |

| **Medication use** | | | | |
| Vitamin K antagonist, n (%) | 12 (15) | 1 (3) | 0.11 | 7 (21) | 0 | 0.06 |
| Vitamin D analogue, n (%) | 61 (75) | 32 (89) | 0.15 | 29 (85) | 19 (83) | 0.99 |
| Calcium-containing phosphate binder, n (%) | 28 (35) | 14 (39) | 0.81 | 18 (53) | 10 (44) | 0.67 |
| Cinacalcet, n (%) | 16 (20) | 7 (19) | 0.99 | 8 (24) | 3 (13) | 0.52 |

| **Laboratory parameters** | | | | |
| Calcium, mmol/L | 2.3±0.1 | 2.4±0.1 | 0.01 | 2.3±0.1 | 2.4±0.1 | 0.01 |
| Albumin, g/L | 41.4±3.2 | 38.3±3.3 | <0.001 | 40.8±3.0 | 38.5±3.5 | 0.02 |
| Phosphate, mmol/L | 1.6±0.4 | 1.6±0.4 | 0.69 | 1.6±0.3 | 1.6±0.3 | 0.50 |
| C-reactive protein, mg/L | 3 (2–6) | 3 (1–13) | 0.93 | 2 (2–7) | 2 (1–18) | 0.91 |
| Parathyroid hormone, pmol/L | 22 (15–41) | 22 (14–37) | 0.53 | 30 (17–48) | 22 (15–41) | 0.53 |

Data are presented as mean ± SD, median (IQR) or number (%). * In the cross-sectional cohort, data on medication use were available in 81 patients on hemodialysis and 36 patients on peritoneal dialysis; in the longitudinal cohort data on medication use were available in all patients. CAC, coronary artery calcification.
Fig. 1. CAC progression in 57 patients on dialysis stratified by dialysis modality, depicted as individual trajectories of calcium volume scores. Individual trajectories of change in calcium volume score in patients on hemodialysis (left panel) and patients on peritoneal dialysis (right panel). Trajectories of 2 patients on hemodialysis and one on peritoneal dialysis with scores > 5,000 are not shown in this figure. Number of patients shown at 0, 1, 2, and 3 years: hemodialysis 32, 32, 21, and 10; peritoneal dialysis: 22, 22, 7, and 4. Note that lines may overlap around 0.

Fig. 2. CAC progression per year in 57 patients on dialysis stratified by dialysis modality, depicted as boxplots of change in square root transformed volume score. Change in square root transformed volume scores (Y-axis) stratified by dialysis modality (X-axis) as boxplots. Note that square root transformations cannot be back-transformed. Number of patients per group per period (N) denoted below the boxplots. Crude P for difference in change in square root transformed volume score per year: 0.18; adjusted P for difference in change in square root transformed volume score per year: 0.03.
associated with higher ΔCAC SQRV than hemodialysis in unadjusted analyses (difference in ΔCAC SQRV per year 1.01; 95% CI –0.47 to 2.47). When adjusted for CAC SQRV at inclusion, age, sex, diabetes mellitus, dialysis vintage, vitamin K antagonist use, and presence of residual urine production, peritoneal dialysis was significantly (p = 0.03) associated with 1.20 ΔCAC SQRV per year higher CAC progression compared to hemodialysis (95% CI 0.09–2.31).

In Tobit mixed models, CAC progressed with 99 mm³ per year in hemodialysis (95% CI –42 to 240) and with 288 mm³ per year in peritoneal dialysis (95% CI 57 to 519). As can be seen in Table 2, peritoneal dialysis was not significantly associated with higher CAC progression than hemodialysis in both crude and adjusted analyses with Tobit mixed models (crude difference 189 mm³ per year; 95% CI –81 to 459; p = 0.17; and fully adjusted difference 106 mm³ per year; 95% CI –140 to 352; p = 0.40).

**Calcification Biomarkers**

At inclusion, we measured calcification biomarkers in the longitudinal cohort (n = 57). Dp-ucMGP levels were median 1,689 (IQR 1,304–3,470) pmol/L in hemodialysis, and 1,548 (IQR 900–1,822) pmol/L in peritoneal dialysis. Fetuin-A levels were mean 0.20 ± 0.06 g/L in hemodialysis and 0.21 ± 0.08 g/L in peritoneal dialysis. Osteoprotegerin were mean 3.2 ± 1.4 µg/L in hemodialysis and 3.3 ± 1.2 µg/L in peritoneal dialysis. In univariate analyses, peritoneal dialysis was not associated with differences in dp-ucMGP, fetuin-A, or osteoprotegerin levels (online suppl. Table S2). When adjusted for age, sex, diabetes mellitus, dialysis vintage, vitamin K antagonist use, and presence of residual urine production, peritoneal dialysis was associated with 0.83 µg/L higher osteoprotegerin levels than hemodialysis (95% CI 0.13 to 1.52; p = 0.02), but not with differences in dp-ucMGP or fetuin-A. Osteoprotegerin correlated with ΔCAC SQRV (Pearson’s correlation coefficient 0.32, p = 0.05), while dp-ucMGP and fetuin-A did not correlate with ΔCAC SQRV (Pearson’s correlation coefficients 0.23, p = 0.13; and –0.01, p = 0.93).

### Table 2. Effect estimates of CAC progression for peritoneal dialysis (n = 23) compared to hemodialysis (n = 34) analyzed with linear mixed models as ΔCAC SQRV and with Tobit mixed models, with different multivariate adjustments

<table>
<thead>
<tr>
<th></th>
<th>Unadjusted</th>
<th>CAC SQRV at inclusion*</th>
<th>Adjustment for age and gender†</th>
<th>Full adjustment‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ΔCAC SQRV</strong></td>
<td>1.01 (–0.47 to 2.47)</td>
<td>1.22 (0.16 to 2.29)</td>
<td>1.25 (0.19 to 2.33)</td>
<td>1.20 (0.09 to 2.31)</td>
</tr>
<tr>
<td>Tobit regression</td>
<td>189 (–81 to 459)</td>
<td>–</td>
<td>77 (–184 to 338)</td>
<td>106 (–140 to 352)</td>
</tr>
</tbody>
</table>

*Tobit mixed models could not be adjusted for CAC SQRV at inclusion.
†The linear mixed models of ΔCAC SQRV were additionally adjusted for CAC SQRV at inclusion.
‡Full adjustment included age, sex, diabetes mellitus, dialysis vintage, presence of residual urine production, and vitamin K antagonist use. The linear mixed models of ΔCAC SQRV were additionally adjusted for CAC SQRV at inclusion 95% CI between brackets.
CAC, coronary artery calcification.

### Discussion

Our study investigated whether vascular calcification develops less in peritoneal dialysis than in hemodialysis, cross-sectionally and longitudinally. In a large cross-sectional cohort, we found that patients treated with peritoneal dialysis do not have less CAC than patients treated with hemodialysis. In the longitudinal cohort, we found that patients on peritoneal dialysis do not have less CAC progression than patients on hemodialysis. Altogether, this indicates that vascular calcification does not develop less in peritoneal dialysis than in hemodialysis.

Few studies have compared vascular calcification between hemodialysis and peritoneal dialysis, that is, 3 cross-sectional studies and one longitudinal study. An American cross-sectional study found more frequent CAC in pediatric patients on hemodialysis (9/21 patients) than on peritoneal dialysis (2/17 patients) [11]. An Albanian cross-sectional study found more frequent cardiac valve calcification in adult patients on hemodialysis (24/34 patients) than on peritoneal dialysis (10/30 patients) [12]. A Korean cross-sectional study did not find a significant difference in CAC score between patients on hemodialysis (n = 31, median score 30) and those on peritoneal dialysis (n = 15, median score 16) [13]. Finally, a Taiwanese study did not find significant differences in
Coronary Calcification in HD and PD

Our findings regarding the 3 calcification biomarkers do not allow firm conclusions and need further exploration. First, we found that osteoprotegerin was associated with progression of CAC, in accordance with previous studies [28, 29]. Nevertheless, osteoprotegerin should theoretically protect against vascular calcification by preventing the receptor activator of nuclear factor-κB ligand from binding to the RANK receptor [30]. Whether our finding indicates a compensatory response requires additional study. Second, we did not find a significant association between CAC progression and dp-ucMGP. Dp-ucMGP is an inverse marker of calcification inhibition potential, as its active form inhibits vascular calcification after carboxylation by vitamin K [31]. It is possible that larger samples are needed to study the relationship between CAC progression and dp-ucMGP. Third, we did not find any relationship between fetuin-A and CAC progression. Fetuin-A is a hepatic protein that forms soluble complexes with calcium and phosphate (calciprotein particles [CPPs]) and thus prevents calcification [32]. The reason we did not find a relationship with CAC progression lies probably in these CPPs: an ordinary fetuin-A measurement includes the CPP-bound fetuin-A, which is the fetuin-A fraction that has already been used up. Future studies should measure the non-CPP-bound fraction of fetuin-A after an extra centrifugation step [33], or should measure CPPs directly [34].

Our results should be interpreted within certain limitations. The size of our longitudinal cohort was small and patients on peritoneal dialysis had a limited follow-up duration. Larger studies are necessary to investigate whether peritoneal dialysis may be associated with more CAC than hemodialysis and to investigate the relationship between calcification biomarkers and CAC progression. Also, our study was non-randomized, although randomization to dialysis modalities has proven infeasible in earlier studies [9].

Our study has several strengths as well. This study is the largest so far to compare vascular calcification between hemodialysis and peritoneal dialysis, combining a large cross-sectional cohort with follow-up data on progression of CAC. Also, we accounted for the skewness and zero-inflation of CAC scores by using 2 statistically valid approaches that enabled essential adjustment for potential confounders. Moreover, the patients on hemodialysis and peritoneal dialysis in our study were relatively comparable, as this study only included patients eligible for transplantation.

In conclusion, peritoneal dialysis is not associated with less CAC nor less CAC progression than hemodialysis. This indicates that vascular calcification does not develop...
less in peritoneal dialysis. Further studies should investigate whether vascular calcification develops even more in peritoneal dialysis.

Acknowledgments

We thank the following centers for recruiting patients for the NOCTx study: Dialysecentrum Groningen, Groningen, the Netherlands; Diaprica Dialysecentrum and VU Medisch Centrum, Amsterdam, the Netherlands; Meander Medisch Centrum, Amersfoort, the Netherlands; Rijnstate Ziekenhuis, Arnhem, the Netherlands; Sint Antoniusziekenhuis, Nieuwegein, the Netherlands; Stichting Dianeet Dialysecentra and Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands. We thank Dr. L.J. Schurgers for providing the dp-acMGP measurements, and Dr. I. Hoefer for the fetuin-A and osteoprotegerin measurements.

Ethics Statement

All subjects provided written informed consent. The study protocol has been approved by the Medical Ethics Committee of the University Medical Center Utrecht and the study was conducted according to the Declaration of Helsinki.

References

Coronary Calcification in HD and PD